-
US, UK and Germany are top manufacturers for COVID-19 vaccines
expresspharma
November 20, 2020
Vaccine developers are selecting manufacturers that are closer to their homes, which could be due to storage or manufacturing availability.
-
COVID-19 vaccine from AstraZeneca produces immune response in elderly
expresspharma
November 20, 2020
AstraZeneca and Oxford University’s potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.
-
EU signs COVID-19 vaccine deal with CureVac
pharmatimes
November 19, 2020
The European Commission has signed a contract with CureVac for access to 405 million doses of its investigational COVID-19 vaccine.
-
Pfizer, BioNTech’s final Covid-19 vaccine study shows 95% efficacy
pharmaceutical-technology
November 19, 2020
Pfizer and BioNTech have concluded the Phase III study of their mRNA-based Covid-19 vaccine candidate, BNT162b2, which showed 95% efficacy rate and met all primary efficacy endpoints.
-
CoronaVac from Sinovac triggers quick immune response
expresspharma
November 19, 2020
The Sinovac findings came from results in Phase I and Phase II clinical trials in China involving over 700 participants.
-
COVID-19 vaccines production driving contract service agreements
expresspharma
November 19, 2020
Most contract manufacturing service agreements are for recombinant vector vaccines, followed by subunit vaccines.
-
EMA releases safety monitoring plan for COVID-19 vaccines
europeanpharmaceuticalreview
November 18, 2020
The EMA’s safety monitoring plan outlines how new information after authorisation of COVID-19 vaccines will be collected and reviewed.
-
UK strikes deal for five million doses of Moderna’s COVID-19 vaccine
pharmatimes
November 18, 2020
The UK government has secured access to five million doses of Moderna’s COVID-19 vaccine after interim data, released yesterday, suggested that the shot is 94.5% effective.
-
Inovio to start mid-stage trials of its COVID-19 vaccine
expresspharma
November 18, 2020
The US FDA had put Phase 3 of the mid-to-late stage trial on hold, and sought more information, including details on a delivery device used to inject genetic material into cells.
-
Pfizer to commence pilot delivery programme for COVID-19 vaccine in the US
expresspharma
November 18, 2020
Pfizer has launched a pilot delivery programme for its experimental COVID-19 vaccine in four US states, as the company seeks to address distribution challenges due to ultra-cold storage requirements.